NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL ®, indicated for steroid-refractory acute graft-versus ...
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL ®, indicated for steroid-refractory acute graft ...
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback